Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of PBF-999 in Prader-Willi Syndrome
2022-501462-22-00Phase 2Completed
- Sponsor
- Palobiofarma
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing PBF-999 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Dec 2022; status: completed.
02
Drugs
PBF-999
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2022-501462-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501462-22-00.